

DEPARTMENT OF JUSTICE**Drug Enforcement Administration****[Docket No. DEA-372]****Exempt Chemical Preparations Under the Controlled Substances Act****AGENCY:** Drug Enforcement Administration, Department of Justice.**ACTION:** Order with opportunity for comment.

SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous **Federal Register** notices, and it does not affect preparations that have been previously published.

DATES: Comments must be submitted electronically or postmarked on or before October 13, 2026.

ADDRESSES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please reference "Docket No. DEA-372" on all correspondence, including any attachments.

- *Electronic comments:* The Drug Enforcement Administration (DEA) encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or to attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on *Regulations.gov*. If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.

- *Paper comments:* Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment *in lieu of* an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration,

Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

- *Paperwork Reduction Act*
Comments: All comments concerning collections of information under the Paperwork Reduction Act must be submitted to the Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for DOJ, Washington, DC 20503. Please state that your comment refers to Docket No. DEA-1189.

FOR FURTHER INFORMATION CONTACT:

Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (571) 362-8201.

SUPPLEMENTARY INFORMATION:**Posting of Public Comments**

Please note that all comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration (DEA) will make comments available for public inspection online at <http://www.regulations.gov>. Such information includes personal or business identifiers (such as name, address, state or Federal identifiers, etc.) voluntarily submitted by the commenter. Generally, all information voluntarily submitted by the commenter, unless clearly marked as Confidential Information in the method described below, will be publicly posted. Comments may be submitted anonymously. The Freedom of Information Act applies to all comments received.

Commenters submitting comments which include personal identifying information (PII), confidential, or proprietary business information that the commenter does not want made publicly available should submit two copies of the comment. One copy must be marked "CONTAINS CONFIDENTIAL INFORMATION" and should clearly identify all PII or business information the commenter does not want to be made publicly available, including any supplemental materials. DEA will review this copy, including the claimed PII and confidential business information, in its consideration of comments. The second copy should be marked "TO BE PUBLICLY POSTED" and must have all claimed confidential PII and business information already redacted. DEA will post only the redacted comment on <http://www.regulations.gov> for public inspection.

For easy reference, an electronic copy of this document and supplemental information to this proposed scheduling action are available at <http://www.regulations.gov>.

Legal Authority

Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).¹ DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

Exempt Chemical Preparation Applications Submitted Between March 1, 2026, and June 30, 2026

DEA received applications between March 1, 2026, and June 30, 2026, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. This publication addresses preparations through June 30, 2026, that were not included in previous **Federal Register** notices, and it does not affect preparations that have been previously published. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or

¹ This authority has been delegated from the Attorney General to the DEA Administrator by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0.

have ill effects, if abused, and so that the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822–823, 825–829, and 952–954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted

to DEA in the form(s) listed in this order and only for those above-mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)–(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)–(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunities for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be

distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between March 1, 2026, and June 30, 2026, and not otherwise referenced in this order or in prior orders, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future **Federal Register** publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

BILLING CODE 4410-09-P

Chart I

Supplier Name	Product Name	Form	Application Date
Abbott	ARCHITECT 2nd Generation Testosterone Calibrators	Kit: 6 bottles, 4 mL each	6/15/2026
Abbott	ARCHITECT 2nd Generation Testosterone Controls	Kit: 3 bottles, 8 mL each	6/15/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica	Kit: 10 glass vials, 3 mL each	6/2/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica Set 2 Level A	Glass vial: 3 mL	6/2/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica Set 2 Level B	Glass vial: 3 mL	6/2/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica Set 2 Level C	Glass vial: 3 mL	6/2/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica Set 2 Level D	Glass vial: 3 mL	6/2/2026
Audit MicroControls, Inc.	Linearity FD Fertility for Siemens Atellica Set 2 Level E	Glass vial: 3 mL	6/2/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Kit	Kit: 10 dropper bottles, 2 mL each	5/8/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Set 2 Level A	Dropper bottle: 2 mL	5/8/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Set 2 Level B	Dropper bottle: 2 mL	5/8/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Set 2 Level C	Dropper bottle: 2 mL	5/8/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Set 2 Level D	Dropper bottle: 2 mL	5/8/2026
Audit MicroControls, Inc.	Linearity FLQ Fertility for Siemens Atellica Set 2 Level E	Dropper bottle: 2 mL	5/8/2026
Biosynth International, Inc.	5-Methoxy-N,N-dimethyltryptamine (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Diazepam (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Mescaline hydrochloride (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Midazolam hydrochloride (1 mg/mL in methanol)	Amber vial: 1 mL	4/13/2026
Biosynth International, Inc.	N,N-Dimethyltryptamine (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Psilocin (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Psilocybin (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Biosynth International, Inc.	Retigabine hydrochloride (1 mg/mL in methanol)	Amber vial: 1 mL	4/27/2026
Cayman Chemical Company	4-Androstenediol (exempt preparation) 1 mg/mL in acetonitrile	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	4-Androstenediol (exempt preparation) 1 mg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026

Cayman Chemical Company	5-Androstenediol (exempt preparation) 1 mg/mL in acetonitrile	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	5-Androstenediol (exempt preparation) 1 mg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	Metonitazene (CRM) 100 µg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	N-desethyl Isotonitazene (CRM) 1 mg/mL in 1 mL Acetonitrile	Glass Ampule: 1 mL	4/30/2026
Cayman Chemical Company	N-desethyl Isotonitazene (CRM) 1 mg/mL in 1 mL Methanol	Glass Ampule: 1 mL	4/30/2026
Cayman Chemical Company	N-Piperidinyl Etonitazene (CRM) 1 mg/mL in 1 mL Acetonitrile	Glass Ampule: 1 mL	4/30/2026
Cayman Chemical Company	N-Piperidinyl Etonitazene (CRM) 1 mg/mL in 1 mL Methanol	Glass Ampule: 1 mL	4/30/2026
Cayman Chemical Company	Protonitazene (CRM) 100 µg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	Testosterone Cypionate (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1.0 mL	5/14/2026
Cayman Chemical Company	Testosterone Cypionate (CRM) 1 mg/mL in methanol	Glass ampule: 1.0 mL	5/14/2026
Cayman Chemical Company	Testosterone Enanthate (CRM) 1 mg/mL in acetonitrile	Glass ampule: 1.0 mL	5/14/2026
Cayman Chemical Company	Testosterone Enanthate (CRM) 1 mg/mL in methanol	Glass ampule: 1.0 mL	5/14/2026
Cayman Chemical Company	Δ9-THC-d3 (CRM) 1 mg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026
Cayman Chemical Company	Δ9-THC-d3 (CRM) 100 µg/mL in methanol	Glass ampule: 1.0 mL	6/16/2026
Cerilliant Corporation	AM-2201 4-hydroxypentyl metabolite	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	AM-2201 4-hydroxypentyl metabolite-D5	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	Bromazolam	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	Bromazolam-13C6	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	Clonitazene-13C6 HCl 0.1 mg/mL (as free base) in solvent	Glass ampule: 1 mL	5/12/2026
Cerilliant Corporation	Clonitazene-HCl 1.0 mg/mL (as free base) in 1 mL solvent	Glass ampule: 1 mL	6/29/2026
Cerilliant Corporation	Eszopiclone 1.0 mg/mL in solvent	Glass ampule: 1 mL	5/12/2026
Cerilliant Corporation	JWH-018 5-hydroxypentyl metabolite	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-018 N-(4-hydroxypentyl) metabolite	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-018 N-(4-hydroxypentyl) metabolite-D5 (indole-D5)	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-073 4-hydroxybutyl metabolite	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-122 4-hydroxypentyl metabolite-D5	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-210 4-hydroxypentyl metabolite	Glass ampule: 1 mL	4/6/2026
Cerilliant Corporation	JWH-210 5-hydroxypentyl metabolite	Glass ampule: 1 mL	4/6/2026
College of American Pathologists (CAP)	2027 DMPM-01	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 DMPM-02	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 DMPM-03	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 DMPM-05	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 DMPM-06	HDPE bottle: 40 mL	5/5/2026

Pathologists (CAP)		mL	
College of American Pathologists (CAP)	2027 DMPM-07	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-02	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-03	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-04	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-06	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-07	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-08	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-09	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-10	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-11	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-13	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 FTC-14	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-01	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-02	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-03	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-04	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-05	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-06	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-07	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-08	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-10	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-11	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-12	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-13	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-14	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-15	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-16	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-17	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-18	HDPE vial: 2 mL	5/5/2026

College of American Pathologists (CAP)	2027 OFD-19	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 OFD-20	HDPE vial: 2 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-01	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-04	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-05	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-06	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-09	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-10	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-11	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-13	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-14	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 T-15	HDPE bottle: 20 mL	5/5/2026
College of American Pathologists (CAP)	2027 THCB-02	Amber glass vial: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 THCB-03	Amber glass vial: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 THCB-04	Amber glass vial: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 THCB-05	Amber glass vial: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 THCB-06	Amber glass vial: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-01	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-02	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-03	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-04	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-05	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-06	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-07	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-08	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-09	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-10	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-11	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-12	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-13	HDPE bottle: 10 mL	5/5/2026

College of American Pathologists (CAP)	2027 UDS-14	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UDS-15	HDPE bottle: 10 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-01	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-02	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-03	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-06	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-08	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-09	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-11	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-12	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UT-13	HDPE bottle: 50 mL	5/5/2026
College of American Pathologists (CAP)	2027 UTCO-01	HDPE bottle: 40 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-01	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-02	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-03	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-04	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-05	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027 ZE-06	Amber glass vial: 5 mL	5/5/2026
College of American Pathologists (CAP)	2027-OFD-09	HDPE vial: 2 mL	5/5/2026
LGC Clinical Diagnostics, Inc.	DETECTABUSE® Custom Liquid Control Urine	Glass bottle: 5 mL	5/8/2026
LGC Clinical Diagnostics, Inc.	DETECTABUSE® Custom Liquid Control Urine Kit	Kit: 2 glass bottles, 5 mL each	5/8/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Fentanyl 5ng/mL Positive & Negative, 5mL	Glass bottle: 5 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Fentanyl 5ng/mL Positive & Negative, 5mL KIT	Kit: Glass bottle: 2x5 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen with MDMA, OXY & BUP, POS (2X Cutoff) & NEG	Glass bottle: 20 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen with MDMA, OXY & BUP, POS (2X Cutoff) & NEG KIT	Kit: Glass bottle: 2x20 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen® w/MDMA, OXY & BUP, 2X Cutoff POS	Glass bottle: 5 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen® w/MDMA, OXY & BUP, 2X Cutoff POS & NEG	Glass bottle: 5 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen® w/MDMA, OXY & BUP, 2X Cutoff	Kit: Glass bottle: 2x5 mL	5/28/2026

	POS & NEG KIT		
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen® w/MDMA, OXY & BUP, 2X Cutoff POS KIT	Kit: Glass bottle: 10x5mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen-H with MDMA, OXY & BUP, POS (2X Cutoff) & NEG	Glass bottle: 20 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen-H with MDMA, OXY & BUP, POS (2X Cutoff) & NEG KIT	Kit: Glass bottle: 2x20 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen-H® w/MDMA, OXY & BUP, 2X Cutoff POS	Glass bottle: 5 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	Detectabuse® Stat-Screen-H® w/MDMA, OXY & BUP, 2X Cutoff POS KIT	Kit: Glass bottle: 10x5mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® DOA-Screen Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® DOA-Screen Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® DOA-Screen-H Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® DOA-Screen-H Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 17, Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 17, Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 17H, Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 17H, Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 23, Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 23, Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 23H, Pos & Neg	Glass bottle: 10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	KOVA tox® Detectabuse® Stat-Screen 23H, Pos & Neg KIT	Kit: Glass bottle: 2x10 mL	5/28/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Bulk - Level 1	Plastic/Nalgene bottles or carboys: 16 L	5/15/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Bulk - Level 2	Plastic/Nalgene bottles or carboys: 16 L	5/15/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Bulk - Level 3	Plastic/Nalgene bottles or carboys: 16 L	5/15/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Bulk - Level 4	Plastic/Nalgene bottles or carboys: 16 L	5/15/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Bulk - Level 5	Plastic/Nalgene bottles or carboys: 16 L	5/15/2026
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 504re Working Bulk Level 1	Plastic/Nalgene bottles or carboys: 40 L	5/15/2026
LGC Clinical	VALIDATE Fertility 2 504re Working	Plastic/Nalgene	5/15/2026

Diagnostics, Inc.	Bulk Level 5	bottles or carboys: 40 L	
LGC Clinical Diagnostics, Inc.	VALIDATE Fertility 2 Test Set 504re	5 plastic dropper bottles: 3 mL each	5/15/2026
Lin-Zhi International	6-Acetylmorphine Secondary Stock (1 µg/mL)	Glass or plastic containers: 1 - 250 mL	5/21/2026
Lin-Zhi International	6-Acetylmorphine Secondary Stock (2-5 µg/mL)	Glass or plastic containers: 250 mL	5/21/2026
Lin-Zhi International	6AM 10 ng/mL Bulk Part No.: 1207281	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	6AM 12.5 ng/mL Bulk Part No.: 1207301	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	6AM 20 ng/mL Bulk Part No.: 1207286	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	6AM 40 ng/mL Bulk Part No.: 1207291	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	6AM 5 ng/mL Bulk Part No.: 1207276	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	6AM 7.5 ng/mL Bulk Part No.: 1207296	Glass or plastic containers: 1 mL- 100 L	5/18/2026
Lin-Zhi International	FEN1-26006-0101	20 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0102	20 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0103	20 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0201	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0202	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0203	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0204	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0205	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0206	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0207	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0208	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0209	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0210	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0301	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0302	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0401	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0402	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0501	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0502	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0503	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0504	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0505	10 mL bottle	6/13/2026
Lin-Zhi International	FEN1-26006-0601	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0602	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06026	3 mL vials	6/13/2026

Lin-Zhi International	FEN1-26006-06027	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06028	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06029	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0603	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06030	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06031	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06032	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06033	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06034	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06035	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06036	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06037	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06038	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06039	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0604	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06040	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06041	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06042	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06043	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06044	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06045	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06046	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06047	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06048	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06049	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0605	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06050	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06051	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06052	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06053	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06054	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06055	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06056	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06057	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06058	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06059	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0606	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06060	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06061	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06062	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06063	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06064	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06065	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06066	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06067	3 mL vials	6/13/2026

Lin-Zhi International	FEN1-26006-06068	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06069	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0607	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06070	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06071	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06072	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06073	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06074	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06075	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06076	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06077	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06078	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06079	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0608	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-06080	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06081	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06082	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06083	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06084	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06085	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06086	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06087	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06088	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06089	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06090	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06091	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06092	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06093	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06094	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06095	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06096	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06097	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06098	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06099	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-06100	3 mL vials	6/13/2026
Lin-Zhi International	FEN1-26006-0701	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0702	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0703	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0704	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0705	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0706	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0707	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0708	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0709	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0710	Bottle: 10 mL	6/13/2026

Lin-Zhi International	FEN1-26006-0802	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0803	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0804	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0901	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-0902	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-1001	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN1-26006-1002	Bottle: 10 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11027	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11028	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11029	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11030	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11031	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11032	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11033	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11034	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11035	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11036	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11037	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11038	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11039	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11040	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11041	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11042	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11043	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11044	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11045	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11046	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11047	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11048	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11049	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11050	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11051	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11052	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11053	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11054	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11055	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11056	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11057	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11058	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11059	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11060	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11061	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11062	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11063	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11064	Vial: 3 mL	6/13/2026

Lin-Zhi International	FEN3-26006-11065	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11066	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11067	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11068	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11069	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11070	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11071	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11072	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11073	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11074	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11075	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11076	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11077	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11078	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11079	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11080	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11081	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11082	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11083	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11084	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11085	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11086	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11087	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11088	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11089	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11090	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11091	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11092	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11093	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11094	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11095	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11096	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11097	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11098	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11099	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11100	Vial: 3 mL	6/13/2026
Lin-Zhi International	FEN3-26006-11101	Vial: 3 mL	6/13/2026
Lin-Zhi International	HYD Validation Sample Set 1	Kit: 4 bottles, 20 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 10	Kit: 6 bottles, 10 mL each; 1 vial, 3 mL	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 11	Kit: 2 bottles, 10 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 12	Kit: 123 vials, 3 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 2	Kit: 9 bottles, 10 mL each	6/17/2026

Lin-Zhi International	HYD Validation Sample Set 3	Kit: 19 bottles, 10 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 4	Kit: 6 bottles, 10 mL each; 1 vial, 3 mL	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 5	Kit: 2 bottles, 10 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 6	Kit: 123 vials, 3 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 7	Kit: 4 bottles, 20 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 8	Kit: 11 bottles, 10 mL each	6/17/2026
Lin-Zhi International	HYD Validation Sample Set 9	Kit: 20 bottles, 10 mL each	6/17/2026
Lin-Zhi International	KET Validation Sample Set 4 Item #: KET-26006-0402	Plastic bottle: 10 mL	6/13/2026
Lin-Zhi International	KET Validation Sample Set 5 Item #: KET-26006-0502	Plastic bottle: 10 mL	6/13/2026
Lin-Zhi International	LZI Cannabinoid Calibrator (Oral Fluid) Δ^9 -THC, Cutoff Calibrator (4 ng/mL)	Amber bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoid Calibrator (Oral Fluid) Δ^9 -THC, High Calibrator (20 ng/mL)	Amber bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoid Calibrator/Control (Oral Fluid) Δ^9 -THC, Intermediate Calibrator/Level 2 (8 ng/mL)	Amber bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoid Calibrator/Control (Oral Fluid) Δ^9 -THC, Low Calibrator/Level 1 Control	Amber bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Calibrator (Oral Fluid) Δ^9 -THC, Cutoff Calibrator (4 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Calibrator (Oral Fluid) Δ^9 -THC, High Calibrator (12 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Calibrator (Oral Fluid) Δ^9 -THC, Intermediate Calibrator (6 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Calibrator (Oral Fluid) Δ^9 -THC, Low Calibrator (2 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Control (Oral Fluid) Δ^9 -THC, Level 1 Control (3 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Cannabinoids Control (Oral Fluid) Δ^9 -THC, Level 2 Control (5 ng/mL)	Amber bottle: 15 mL	6/10/2026
Lin-Zhi International	LZI Ecstasy Calibrator (Oral Fluid) MDMA, Cutoff Calibrator	Dropper bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Ecstasy Calibrator (Oral Fluid) MDMA, High Calibrator	Dropper bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Intermediate Calibrator/Level 2 Control	Dropper bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Ecstasy Calibrator/Control (Oral Fluid) MDMA, Low Calibrator/Level 1 Control	Dropper bottle: 5 mL	6/10/2026
Lin-Zhi International	LZI Propoxyphene Calibrator (Oral	Dropper bottle: 5	5/21/2026

	Fluid) Propoxyphene, Cutoff Calibrator	mL	
Lin-Zhi International	LZI Propoxyphene Calibrator (Oral Fluid) Propoxyphene, High Calibrator	Dropper bottle: 5 mL	5/21/2026
Lin-Zhi International	LZI Propoxyphene Calibrator/Control (Oral Fluid) Propoxyphene, Intermediate Calibrator/Level 2 Control	Dropper bottle: 5 mL	5/21/2026
Lin-Zhi International	LZI Propoxyphene Calibrator/Control (Oral Fluid) Propoxyphene, Low Calibrator/Level 1 Control	Dropper bottle: 5 mL	5/21/2026
Research Triangle Institute	U1427, U1974, U1965, U1102, U1982, U1193, U1728, U1166, U1931, U1287, U1975, U1626, U1258, U1600, U1215, U1954, U1845, U1871, U1231, U1239, U1434, U1414, U1315, U1854, U1333, U1510, U1262, U1946, U1936, U1511	HDPE bottle: 25 mL	5/13/2026
Research Triangle Institute	U3704, U3183, U3237, U3323, U3236, U3840, U3552, U3881, U3914, U3528, U3345, U3472, U3458, U3889, U3015, U3481, U3637, U3240, U3055, U3619, U3279, U3987, U3857, U3347, U3590, U3950, U3390, U3558, U3582, U3966	HDPE bottle: 25 mL	5/13/2026
Research Triangle Institute	U4241, U4851, U4087, U4772, U4140, U4296, U4096, U4468, U4976, U4351, U4878, U4546, U4843, U4512, U4867, U4607, U4743, U4048, U4775, U4614, U4406, U4739, U4932, U4820, U4024, U4544, U4870, U4370, U4184, U4865	HDPE bottle: 25 mL	5/13/2026
Restek Corporation	Custom Pregabalin Standard	Glass ampule: 1.3 mL	6/5/2026
Revvity	CP 55940, [Side Chain-2,3,4-3H(N)]-, 25 µCi Product No. NET105125UC	Plastic Vial: 0.025 mL	5/18/2026
Revvity	CP 55940, [Side Chain-2,3,4-3H(N)]-, 250 µCi Product No. NET1051250UC	Plastic Vial: 0.25 mL	5/18/2026
RTI International	2027 NOB-02	Amber glass vial: 15 mL	6/2/2026
RTI International	2027 NOB-03	Amber glass vial: 15 mL	6/2/2026
RTI International	2027 NOB-04	Amber glass vial: 15 mL	6/2/2026
RTI International	2027 NOB-05	Amber glass vial: 15 mL	6/2/2026
RTI International	2027 SCDD-01	HDPE bottle: 10 mL	6/2/2026
RTI International	2027 SCDD-02	HDPE bottle: 10 mL	6/2/2026
RTI International	2027 SCDD-03	HDPE bottle: 10 mL	6/2/2026
RTI International	2027 SCDD-04	HDPE bottle: 10 mL	6/2/2026
RTI International	2027 SCDD-05	HDPE bottle: 10 mL	6/2/2026
RTI International	2027 SCDD-06	HDPE bottle: 10 mL	6/2/2026

		mL	
RTI International	2027 SDT-01	Amber glass vial: 5 mL	6/2/2026
RTI International	2027 SDT-02	Amber glass vial: 5 mL	6/2/2026
RTI International	2027 SDT-03	Amber glass vial: 5 mL	6/2/2026
RTI International	2027 SDT-04	Amber glass vial: 5 mL	6/2/2026
RTI International	2027 SDT-05	Amber glass vial: 5 mL	6/2/2026
RTI International	2027 SDT-06	Amber glass vial: 5 mL	6/2/2026
Technopath Clinical Diagnostics	Multichem IA Control 1 (IA301X)	Glass vial: 5 mL	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control 1 Kit (IA301X)	Kit: 12 glass vials, 5 mL each	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control 2 (IA302X)	Glass vial: 5 mL	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control 2 Kit (IA302X)	Kit: 12 glass vials, 5 mL each	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control 3 (IA303X)	Glass vial: 5 mL	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control 3 Kit (IA303X)	Kit: 12 glass vials, 5 mL each	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Control Kit (IA300X)	Kit: 12 glass vials, 5 mL each	6/16/2026
Technopath Clinical Diagnostics	Multichem IA Plus Control 1	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem IA Plus Control 2	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem IA Plus Control 3	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem IA Plus Kit	12 amber bottles or vials: 5 mL each	4/22/2026
Technopath Clinical Diagnostics	Multichem IA Tri level assayed Kit (IA300A)	Kit: 12 glass vials, 5 mL each	6/16/2026
Technopath Clinical Diagnostics	Multichem S Control 1	Amber vials: 5 mL, 10 mL	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 1 Kit (CH101A)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 1 Kit (CH101A.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 1 Kit (CH101X)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 1 Kit (CH101X.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 2	Amber vials: 5 mL, 10 mL	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 2 Kit (CH102A)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 2 Kit (CH102A.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 2 Kit (CH102X)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 2 Kit (CH102X.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 3	Amber vials: 5 mL, 10 mL	6/11/2026

Technopath Clinical Diagnostics	Multichem S Control 3 Kit (CH103A)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 3 Kit (CH103A.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 3 Kit (CH103X)	15 amber vials, 10 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Control 3 Kit (CH103X.05)	12 amber vials, 5 mL each	6/11/2026
Technopath Clinical Diagnostics	Multichem S Plus (Assayed) Control 1	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem S Plus (Assayed) Control 2	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem S Plus (Assayed) Control 3	Amber bottle or vial: 5 mL	4/22/2026
Technopath Clinical Diagnostics	Multichem S Plus (Assayed) Kit	12 amber bottles or vials: 5 mL each	4/22/2026

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II, below, is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the Assistant

Administrator has determined that the chemical preparations or mixtures generally described in Chart II, below, and specifically described in the application materials received by DEA, are not exempt from application of any part of the CSA or from application of

any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

Chart II

Supplier Name	Product Name	Form	Application Date
Biosynth International, Inc.	Midazolam hydrochloride; 1 mg/mL in Methanol	Amber vial: 10 mL	4/7/2026
Cerilliant Corporation	Performance Solution-13 (0.25 mg/mL in solvent)	Glass ampule: 1 mL	6/2/2026
Diagnostica Stago Inc.	STA®—Owren-Koller	Plastic Vial: 15 mL	5/15/2026
LGC Clinical Diagnostics, Inc.	Codeine 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Fentanyl 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Hydrocodone 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Hydromorphone 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Morphine 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Morphine-3-β-D-glucuronide 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Norbuprenorphine 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Norfentanyl 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Oxycodone 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
LGC Clinical Diagnostics, Inc.	Oxymorphone 1 mg/mL in Methanol	Plastic bottle: 50 mL	3/26/2026
Lin-Zhi International	6-Acetylmorphine Secondary Stock	Glass or plastic containers: 1 mL-250 mL	5/18/2026

BILLING CODE 4410-09-C

Opportunity for Comment

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until she may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as she determines appropriate.

Approved Exempt Chemical Preparations Are Posted on DEA's website

A list of all current exemptions, including those listed in this order, is available on DEA's website at http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf. The dates of applications of all current exemptions are posted for easy reference.

Signing Authority

This document of the Drug Enforcement Administration was signed on August 12, 2026, by DEA Assistant Administrator Cheri Oz. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,
Federal Register Liaison Officer, Drug
Enforcement Administration.

[FR Doc. 2026-16665 Filed 8-13-26; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE**Notice of Lodging of Proposed Consent Decree Under the Safe Drinking Water Act**

On August 12, 2026, the Department of Justice lodged a Consent Decree ("Decree") with the United States District Court for the District of New

Jersey in the lawsuit entitled *United States, et. al. v. Passaic Valley Water Commission*, Civil Action No. 2:26-cv-10199.

The proposed Consent Decree resolves alleged violations of Section 141.714 of the Long Term 2 Enhanced Surface Water Treatment Rule ("LT2 Rule"), 40 CFR 141.714, promulgated under Section 1412 of the Safe Drinking Water Act, 42 U.S.C. 300g-1. The alleged violations of the LT2 Rule pertain to the obligation of Passaic Valley Water Commission ("PVWC") to cover the Great Notch, Levine, and New Street Reservoirs or to treat water discharged from these reservoirs before human consumption. The proposed Consent Decree requires PVWC to pay a civil penalty of \$132,500 to the United States. It also establishes a schedule for PVWC to come into compliance with LT2 and the Safe Drinking Water Act by undertaking feasibility studies and implementation of selected compliance projects. PVWC must also implement interim measures to protect human health and the environment until full compliance is achieved.

The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States, et. al. v. Passaic Valley Commission*, D.J. Ref. No. 90-5-1-1-12573/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

<i>To submit comments:</i>	<i>Send them to:</i>
By email	pubcomment-ees.enrd@usdoj.gov .
By mail	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Any comments submitted in writing may be filed in whole or in part on the public court docket without notice to the commenter. During the public comment period the proposed Consent Decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. If you require assistance accessing the proposed modification, you may request assistance by email or by mail to the

addresses provided above for submitting comments.

Eric D. Albert,

Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.

[FR Doc. 2026-16676 Filed 8-13-26; 8:45 am]

BILLING CODE 4410-CW-P

EXECUTIVE OFFICE OF THE PRESIDENT**Office of National Drug Control Policy**

Paperwork Reduction Act; Proposed Collection; Comment Request; Revisions of Currently Approved Collection: Drug-Free Communities (DFC) Support Program and Community-Based Coalition Enhancement Grants To Address Local Drug Crisis (CARA) Local Drug Crisis Program National Evaluation

AGENCY: Office of National Drug Control Policy.

ACTION: 30-Day notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, the Office of National Drug Control Policy (ONDCP) announces it will submit to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs (OIRA) an information collection request.

DATES: ONDCP encourages and will accept public comments on or before 30 days after the date of this publication.

ADDRESSES: Address all comments in writing within 30 days to the Office of Grants and Programs. Email is the most reliable means of communication. The DFC Program inbox is MBX.ONDCP.DFC@ondcp.eop.gov. Mailing address is: Executive Office of the President, Office of National Drug Control Policy, Office of Grants and Programs, Drug-Free Communities (DFC) Support Program, 1800 G Street NW, Suite 9110, Washington, DC 20006.

SUPPLEMENTARY INFORMATION:

Abstract: ONDCP administers the Drug-Free Communities (DFC) Support Program and Community-Based Coalition Enhancement Grants to Address Local Drug Crisis (CARA) Local Drug Crisis Programs. The DFC Program has two primary goals: To reduce youth substance abuse, and to support community anti-drug coalitions by establishing, strengthening, and fostering collaboration among public and private agencies. The CARA Local Drug Crisis grant program funds current or former DFC grant award recipients to